COPENHAGEN, Denmark & TOKYO--(BUSINESS WIRE)--Symphogen A/S and Meiji Seika Kaisha Ltd. (TSE: 2202) announced today that they have entered into a research, development and commercialization agreement that utilizes Symphogen’s proprietary antibody discovery technology, Symplex™, to develop a fully human recombinant polyclonal antibody (pAb) product candidate that targets a non-disclosed bacterial pathogen.
